With 4.9 million shares changed hands, the volume of the stock remained heavier than its average volume of 2.7 million shares. During the session, the Medical Devices company that operates in wider Healthcare sector, reached to the highest price of $10.65 whereas the lowest price it dropped to was $9.25. The 52-week range on NNOX shows that it touched its highest point at $14.28 and its lowest point at $5.26 during that stretch. It currently has a 1-year price target of $15.00. Beta for the stock currently stands at 1.97.
Price Performance and Earnings:
Stock performance is one of the indicators that investors use to determine whether they will profit from a stock. The price performance of NNOX was up-trending over the past week, with a rise of 25.20%, but this was up by 50.88% over a month. Three-month performance surged to 56.92% while six-month performance rose 24.54%. The stock gained 52.10% in the past year, while it has gained 30.76% so far this year. A look at the trailing 12-month EPS for NNOX yields -0.86 with Next year EPS estimates of -0.70. For the next quarter, that number is -0.23. This implies an EPS growth rate of 17.59% for this year and 20.79% for next year.
Float and Shares Shorts:
At present, 58.52 million NNOX shares are outstanding with a float of 53.02 million shares on hand for trading. On 2024-10-31, short shares totaled 7.25 million, which was 1239.00004 higher than short shares on 1727654400. In addition to Mr. Erez I. Meltzer as the firm’s CEO & Acting Chairman of the Board, Mr. Ran Daniel serves as its Chief Financial Officer.
Institutional Ownership:
Through their ownership of 0.18667 of NNOX’s outstanding shares, institutional investors have minority control over the company.
An Overview of Recent Financials:
Understanding a company as a customer does not mean you will understand it as an investor. The wise investor uses quantitative research to analyze metrics such as revenue, net income, and earnings. In its fiscal quarter reported on 2024-06-30, NNOX reported revenue of $3031000.0 and operating income of -$14139000.0. The EBITDA in the recently reported quarter was -$11210000.0 and diluted EPS was -$0.23.
Analysts Ratings:
Reading analyst opinions is an effective way to decide where to invest, and there are several opinions available for NNOX since 2 analysts follow the stock currently. There are 2 analysts who recommend BUY ratings, while 0 suggest SELL ratings. Of the remaining analysts, 0 believe that the stock is worth HOLDING, 0 give it an OVERWEIGHT rating, and 0 thinks that it’s UNDERWEIGHT. In the same way, a target price assigned to a stock can also reveal much about its potential. With NNOX analysts setting a high price target of 23.0 and a low target of 11.0, the average target price over the next 12 months is 15.0. Based on these targets, NNOX could surge 144.42% to reach the target high and rise by 16.9% to reach the target low. Reaching the average price target will result in a growth of 59.4% from current levels.
Analysts have provided yearly estimates in a range of -$0.87362 being high and -$0.95304 being low. For NNOX, this leads to a yearly average estimate of -$0.91333.
